Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference

NEXT STORY
Updated: Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
PREV STORY
Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Insights on the Liquid Handling System Global Market to 2026 – Competitive Analysis and the Impact of COVID-19

author_avatar
NASDAQ Market News

argenx reports third quarter 2018 financial results and provides business update

October 25, 2018Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), ...

author_avatar
NASDAQ Market News

UPDATE – Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)

author_avatar
NASDAQ Market News